NCT01363167

Brief Summary

This study is to determine the amount of vitamin D required for a very low birth weight infant to reach vitamin D sufficiency and achieve optimal calcium health and bone growth.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
68

participants targeted

Target at P50-P75 for not_applicable

Timeline
Completed

Started Oct 2011

Typical duration for not_applicable

Geographic Reach
1 country

2 active sites

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

April 18, 2011

Completed
1 month until next milestone

First Posted

Study publicly available on registry

June 1, 2011

Completed
4 months until next milestone

Study Start

First participant enrolled

October 1, 2011

Completed
2 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

October 1, 2013

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

October 1, 2013

Completed
Last Updated

November 24, 2014

Status Verified

November 1, 2014

Enrollment Period

2 years

First QC Date

April 18, 2011

Last Update Submit

November 21, 2014

Conditions

Keywords

vitamin Dpreterm infantscalciumboneparathyroid hormone

Outcome Measures

Primary Outcomes (5)

  • Intestinal Calcium Absorption

    When receiving at least 50% of nutrition enterally expected to occur at 2-6 weeks post-birth

  • Parathyroid hormone concentration

    At term age (expected 2-4 months)

  • Serum 25 hydroxyvitamin D status

    At term age (expected 2-4 months)

  • Bone Health

    Bone ultrasound measurement, serum alkaline phosphatase, and bone-specific alkaline phosphatase at birth and monthly until term age. Bone mineralization by DEXA scan at hospital discharge and term age.

    At term age (expected 2-4 months)

  • Serum inflammatory cytokine concentrations

    At birth (day 1)

Secondary Outcomes (3)

  • Phosphorus Homeostasis

    At term age (expected 2-4 months)

  • Growth parameters

    At term age (expected 2-4 months)

  • Vitamin D Dose Safety as Measured by Urinary Calcium Excretion

    At term age (expected 2-4 months)

Study Arms (2)

400 IU Cholecalciferol - Vitamin D

ACTIVE COMPARATOR
Dietary Supplement: 400 IU Cholecalciferol- Vitamin D Daily

Placebo

PLACEBO COMPARATOR

Placebo contains Fractionated Coconut Oil

Dietary Supplement: 400 IU Cholecalciferol- Vitamin D Daily

Interventions

Infants who are defined as vitamin D deficient at birth will be randomized to receive either 400 IU vitamin D/day or placebo daily until term age is reached.

400 IU Cholecalciferol - Vitamin DPlacebo

Eligibility Criteria

Age1 Day - 3 Days
Sexall
Healthy VolunteersNo
Age GroupsChild (0-17)

You may qualify if:

  • Any infant born at the Medical University of South Carolina \<34 weeks gestation
  • Less that 1500g at birth
  • AGA
  • Must be African American or Caucasian
  • Each infant born of twin and triplet pregnancies will be eligible

You may not qualify if:

  • Infants with major congenital anomalies or with hemolytic disease requiring exchange transfusion
  • Infants born small for-gestational-age (SGA) or large for-gestational-age (LGA)
  • Maternal uncontrolled thyroid disease
  • Maternal Parathyroid disease
  • Infants of races other than African American or Caucasian

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (2)

Medical University of South Carolina

Charleston, South Carolina, 29425-8750, United States

Location

Medical University of South Carolina

Charleston, South Carolina, 29425, United States

Location

MeSH Terms

Conditions

Vitamin D Deficiency

Condition Hierarchy (Ancestors)

AvitaminosisDeficiency DiseasesMalnutritionNutrition DisordersNutritional and Metabolic Diseases

Study Officials

  • Sarah N. Taylor, M.D.

    Medical University of South Carolina

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
TRIPLE
Who Masked
PARTICIPANT, CARE PROVIDER, INVESTIGATOR
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Assistant Professor of Pediatrics, Medical University of SC

Study Record Dates

First Submitted

April 18, 2011

First Posted

June 1, 2011

Study Start

October 1, 2011

Primary Completion

October 1, 2013

Study Completion

October 1, 2013

Last Updated

November 24, 2014

Record last verified: 2014-11

Locations